Response to Lavin et al (2025)'s Paper: Cutaneous T-Cell Lymphoma after Dupilumab Use: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System.
Saved in:
| Title: | Response to Lavin et al (2025)'s Paper: Cutaneous T-Cell Lymphoma after Dupilumab Use: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System. |
|---|---|
| Authors: | James ML; St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundational Trust, London, United Kingdom., Pink AE; St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundational Trust, London, United Kingdom., Woolf RT; St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundational Trust, London, United Kingdom., Batty P; London School of Hygiene and Tropical Medicine, London, United Kingdom., Mahil S; St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundational Trust, London, United Kingdom; King's College London, London, United Kingdom., Smith CH; St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundational Trust, London, United Kingdom; King's College London, London, United Kingdom., Whittaker S; St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundational Trust, London, United Kingdom; King's College London, London, United Kingdom. Electronic address: sean.whittaker@kcl.ac.uk., Langan SM; St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundational Trust, London, United Kingdom; London School of Hygiene and Tropical Medicine, London, United Kingdom. |
| Source: | The Journal of investigative dermatology [J Invest Dermatol] 2025 Sep; Vol. 145 (9), pp. 2325-2326. Date of Electronic Publication: 2025 Jun 30. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 0426720 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1523-1747 (Electronic) Linking ISSN: 0022202X NLM ISO Abbreviation: J Invest Dermatol Subsets: MEDLINE; In Process |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
